The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Allogeneic Stem Cell Transplantation Market Research Report 2024
Synopsis
Global Allogeneic Stem Cell Transplantation market is projected to reach US$ 1503.6 million in 2029, increasing from US$ 1000 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Allogeneic Stem Cell Transplantation market research.
Key companies engaged in the Allogeneic Stem Cell Transplantation industry include Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V and Takeda Pharmaceutical Company Limited, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Allogeneic Stem Cell Transplantation were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Allogeneic Stem Cell Transplantation market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Allogeneic Stem Cell Transplantation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Segment by Application
Hospital
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Allogeneic Stem Cell Transplantation report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Allogeneic Stem Cell Transplantation market is projected to reach US$ 1503.6 million in 2029, increasing from US$ 1000 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Allogeneic Stem Cell Transplantation market research.
Key companies engaged in the Allogeneic Stem Cell Transplantation industry include Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V and Takeda Pharmaceutical Company Limited, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Allogeneic Stem Cell Transplantation were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Allogeneic Stem Cell Transplantation market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Allogeneic Stem Cell Transplantation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Segment by Application
Hospital
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Allogeneic Stem Cell Transplantation report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Allogeneic Stem Cell Transplantation Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Unmodified Stem Cell Transplant
1.2.3 T-cell Depleted Transplant
1.2.4 Cord Blood Transplant
1.2.5 Donor Lymphocyte Infusion
1.3 Market by Application
1.3.1 Global Allogeneic Stem Cell Transplantation Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Ambulatory Surgical Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Allogeneic Stem Cell Transplantation Market Perspective (2018-2029)
2.2 Allogeneic Stem Cell Transplantation Growth Trends by Region
2.2.1 Global Allogeneic Stem Cell Transplantation Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Allogeneic Stem Cell Transplantation Historic Market Size by Region (2018-2023)
2.2.3 Allogeneic Stem Cell Transplantation Forecasted Market Size by Region (2024-2029)
2.3 Allogeneic Stem Cell Transplantation Market Dynamics
2.3.1 Allogeneic Stem Cell Transplantation Industry Trends
2.3.2 Allogeneic Stem Cell Transplantation Market Drivers
2.3.3 Allogeneic Stem Cell Transplantation Market Challenges
2.3.4 Allogeneic Stem Cell Transplantation Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Allogeneic Stem Cell Transplantation Players by Revenue
3.1.1 Global Top Allogeneic Stem Cell Transplantation Players by Revenue (2018-2023)
3.1.2 Global Allogeneic Stem Cell Transplantation Revenue Market Share by Players (2018-2023)
3.2 Global Allogeneic Stem Cell Transplantation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Allogeneic Stem Cell Transplantation Revenue
3.4 Global Allogeneic Stem Cell Transplantation Market Concentration Ratio
3.4.1 Global Allogeneic Stem Cell Transplantation Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Allogeneic Stem Cell Transplantation Revenue in 2022
3.5 Allogeneic Stem Cell Transplantation Key Players Head office and Area Served
3.6 Key Players Allogeneic Stem Cell Transplantation Product Solution and Service
3.7 Date of Enter into Allogeneic Stem Cell Transplantation Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Allogeneic Stem Cell Transplantation Breakdown Data by Type
4.1 Global Allogeneic Stem Cell Transplantation Historic Market Size by Type (2018-2023)
4.2 Global Allogeneic Stem Cell Transplantation Forecasted Market Size by Type (2024-2029)
5 Allogeneic Stem Cell Transplantation Breakdown Data by Application
5.1 Global Allogeneic Stem Cell Transplantation Historic Market Size by Application (2018-2023)
5.2 Global Allogeneic Stem Cell Transplantation Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Allogeneic Stem Cell Transplantation Market Size (2018-2029)
6.2 North America Allogeneic Stem Cell Transplantation Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Allogeneic Stem Cell Transplantation Market Size by Country (2018-2023)
6.4 North America Allogeneic Stem Cell Transplantation Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Allogeneic Stem Cell Transplantation Market Size (2018-2029)
7.2 Europe Allogeneic Stem Cell Transplantation Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Allogeneic Stem Cell Transplantation Market Size by Country (2018-2023)
7.4 Europe Allogeneic Stem Cell Transplantation Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Allogeneic Stem Cell Transplantation Market Size (2018-2029)
8.2 Asia-Pacific Allogeneic Stem Cell Transplantation Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Allogeneic Stem Cell Transplantation Market Size by Region (2018-2023)
8.4 Asia-Pacific Allogeneic Stem Cell Transplantation Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Allogeneic Stem Cell Transplantation Market Size (2018-2029)
9.2 Latin America Allogeneic Stem Cell Transplantation Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Allogeneic Stem Cell Transplantation Market Size by Country (2018-2023)
9.4 Latin America Allogeneic Stem Cell Transplantation Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Allogeneic Stem Cell Transplantation Market Size (2018-2029)
10.2 Middle East & Africa Allogeneic Stem Cell Transplantation Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Allogeneic Stem Cell Transplantation Market Size by Country (2018-2023)
10.4 Middle East & Africa Allogeneic Stem Cell Transplantation Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mesoblast Limited
11.1.1 Mesoblast Limited Company Detail
11.1.2 Mesoblast Limited Business Overview
11.1.3 Mesoblast Limited Allogeneic Stem Cell Transplantation Introduction
11.1.4 Mesoblast Limited Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.1.5 Mesoblast Limited Recent Development
11.2 Gamida Cell Ltd.
11.2.1 Gamida Cell Ltd. Company Detail
11.2.2 Gamida Cell Ltd. Business Overview
11.2.3 Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Introduction
11.2.4 Gamida Cell Ltd. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.2.5 Gamida Cell Ltd. Recent Development
11.3 Novartis International AG
11.3.1 Novartis International AG Company Detail
11.3.2 Novartis International AG Business Overview
11.3.3 Novartis International AG Allogeneic Stem Cell Transplantation Introduction
11.3.4 Novartis International AG Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.3.5 Novartis International AG Recent Development
11.4 Cellectis SA
11.4.1 Cellectis SA Company Detail
11.4.2 Cellectis SA Business Overview
11.4.3 Cellectis SA Allogeneic Stem Cell Transplantation Introduction
11.4.4 Cellectis SA Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.4.5 Cellectis SA Recent Development
11.5 Magenta Therapeutics Inc.
11.5.1 Magenta Therapeutics Inc. Company Detail
11.5.2 Magenta Therapeutics Inc. Business Overview
11.5.3 Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Introduction
11.5.4 Magenta Therapeutics Inc. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.5.5 Magenta Therapeutics Inc. Recent Development
11.6 Fate Therapeutics Inc.
11.6.1 Fate Therapeutics Inc. Company Detail
11.6.2 Fate Therapeutics Inc. Business Overview
11.6.3 Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Introduction
11.6.4 Fate Therapeutics Inc. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.6.5 Fate Therapeutics Inc. Recent Development
11.7 Cynata Therapeutics Limited
11.7.1 Cynata Therapeutics Limited Company Detail
11.7.2 Cynata Therapeutics Limited Business Overview
11.7.3 Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Introduction
11.7.4 Cynata Therapeutics Limited Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.7.5 Cynata Therapeutics Limited Recent Development
11.8 Kiadis Pharma N.V
11.8.1 Kiadis Pharma N.V Company Detail
11.8.2 Kiadis Pharma N.V Business Overview
11.8.3 Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Introduction
11.8.4 Kiadis Pharma N.V Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.8.5 Kiadis Pharma N.V Recent Development
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Takeda Pharmaceutical Company Limited Company Detail
11.9.2 Takeda Pharmaceutical Company Limited Business Overview
11.9.3 Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Introduction
11.9.4 Takeda Pharmaceutical Company Limited Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.9.5 Takeda Pharmaceutical Company Limited Recent Development
11.10 JCR Pharmaceuticals Co., Ltd.
11.10.1 JCR Pharmaceuticals Co., Ltd. Company Detail
11.10.2 JCR Pharmaceuticals Co., Ltd. Business Overview
11.10.3 JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Introduction
11.10.4 JCR Pharmaceuticals Co., Ltd. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.10.5 JCR Pharmaceuticals Co., Ltd. Recent Development
11.11 Pluristem Therapeutics Inc.
11.11.1 Pluristem Therapeutics Inc. Company Detail
11.11.2 Pluristem Therapeutics Inc. Business Overview
11.11.3 Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Introduction
11.11.4 Pluristem Therapeutics Inc. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.11.5 Pluristem Therapeutics Inc. Recent Development
11.12 Celularity Inc.
11.12.1 Celularity Inc. Company Detail
11.12.2 Celularity Inc. Business Overview
11.12.3 Celularity Inc. Allogeneic Stem Cell Transplantation Introduction
11.12.4 Celularity Inc. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.12.5 Celularity Inc. Recent Development
11.13 Lineage Cell Therapeutics Inc.
11.13.1 Lineage Cell Therapeutics Inc. Company Detail
11.13.2 Lineage Cell Therapeutics Inc. Business Overview
11.13.3 Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Introduction
11.13.4 Lineage Cell Therapeutics Inc. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.13.5 Lineage Cell Therapeutics Inc. Recent Development
11.14 Nohla Therapeutics Inc.
11.14.1 Nohla Therapeutics Inc. Company Detail
11.14.2 Nohla Therapeutics Inc. Business Overview
11.14.3 Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Introduction
11.14.4 Nohla Therapeutics Inc. Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.14.5 Nohla Therapeutics Inc. Recent Development
11.15 Orchard Therapeutics Plc
11.15.1 Orchard Therapeutics Plc Company Detail
11.15.2 Orchard Therapeutics Plc Business Overview
11.15.3 Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Introduction
11.15.4 Orchard Therapeutics Plc Revenue in Allogeneic Stem Cell Transplantation Business (2018-2023)
11.15.5 Orchard Therapeutics Plc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
